Virtus Health taps into artificial intelligence to improve IVF success rates ZDNet

Virtus Health has announced in partnership with Harrison-AI and Vitrolife that it will commence randomised controlled trials of its artificial intelligence (AI) technology, called Ivy, by the end of the year. Speaking at The Future of Health event in Sydney this week, Virtus Health group CEO Sue Channon explained the tests will be used to further validate the use of AI when it comes to in-vitro fertilisation (IVF). She explained how for the last 12 months, embryologists have been using Ivy as a supporting tool to increase the potential success of pregnancy through IVF. "At this stage Ivy is still a supporting tool, we're not letting Ivy make the decision on its own," she said, explaining how one patient got pregnant during the cycle that Ivy was used after five unsuccessful IVF cycles. "We are seeing an improvement of pregnancy outcome as a result of Ivy."